Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease
Clinical and Molecular Hepatology · 2026
DOI: 10.3350/cmh.2025.0860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Xinrui Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, China. Hauptthemen laut MEDLINE: Hypothyroidism, Fatty Liver. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HKSAR, Gilead Sciences, Illuminatio Medical Technology.
Abstract (Originalsprache)
Background/Aims: Previous studies suggest that hypothyroidism is associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and its histological severity, but clinical outcome data are largely lacking. We aimed to study the impact of hypothyroidism on liver-related events (LREs).
Methods
Patients with MASLD were identified from a territory-wide registry in Hong Kong during 2000–2024. Thyroid status was determined using diagnosis codes and thyroid function tests. The primary outcome, LRE, was defined as a composite of hepatic decompensation, hepatocellular carcinoma, liver transplantation, and liver-related death.
Results
A total of 20,478 patients with MASLD were included in the final analysis (mean age 56.4±13.2 years; 43.9% male). At baseline, 18,178 (88.8%) patients were euthyroid, 598 (2.9%) were hyperthyroid, and 1,702 (8.3%) were hypothyroid. Compared with euthyroid patients, both hyperthyroidism and overt hypothyroidism were associated with cirrhosis. At a median follow-up of 4.8 years, 179 patients developed LREs, and 26 died from liver disease. Compared with patients with normal serum thyroid-stimulating hormone (TSH) levels of 0.4–4 mIU/L, those with subclinical (4–10 mIU/L; adjusted time-dependent cause-specific hazard ratio [aCSHR], 2.49; 95% CI, 1.51–4.13) and overt hypothyroidism (>10 mIU/L; aCSHR, 4.91; 95% CI, 1.56–15.47) had an increased risk of LREs. Time-dependent, but not baseline, TSH and thyroid status were associated with LRE risk.
Conclusions
Subclinical and overt hypothyroidism are associated with an increased risk of LREs in a dose-dependent manner. The association with time-dependent but not baseline thyroid status underscores the importance of thyroid monitoring and suggests that correction of hypothyroidism may mitigate LRE risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, China.
- Medical Data Analytics Center, The Chinese University of Hong Kong, China.
- State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, China.
- Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Förderung
- HKSAR
- Gilead Sciences
- Illuminatio Medical Technology
- Abbott
- Astra Zeneca
- Bayer
- Boehringer Ingelheim
- Dexcom
Zitieren
APA
Jin, X., Song, S. J., Lai, J. C., Wong, G. L., Kong, A. P., Peng, N., Xiao, X., Wong, V. W., & Yip, T. C. (2026). Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.0860
Vancouver
Jin X, Song SJ, Lai JC, Wong GL, Kong AP, Peng N, et al. Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.0860
BibTeX
@article{Jin2026,
author = {Jin, Xinrui and Song, Sherlot Juan and Lai, Jimmy Che-To and Wong, Grace Lai-Hung and Kong, Alice Pik-Shan and Peng, Nana and Xiao, Xiang and Wong, Vincent Wai-Sun and Yip, Terry Cheuk-Fung},
title = {Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2025.0860}
}
EUVIMED